Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean Nolan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 99
- Beta
- 1.17
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 6.53
Financials
Revenue
$0.00-100.0%Net Income
$-39.13MEBITDA
$-38.87MFree Cash Flow
$-33.36MEPS (diluted)
$-0.10Shares Outstanding (diluted)
406.11M+2577.0%Operating Expenses
$41.87MCash & Debt
$422.83MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $9.77M | $-109.00M | $-0.34 |
| 2024 | $8.33M | $-89.30M | $-0.36 |
| 2023 | $15.45M | $-111.57M | $-0.96 |
| 2022 | $2.50M | $-166.01M | $-3.78 |
| 2021 | $0.00 | $-174.52M | $-4.64 |
| 2020 | $0.00 | $-43.00M | $-3.40 |
| 2019 | $0.00 | $-1.11M | $-0.03 |
Valuation
TSHAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-20.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·10d ago·Neutral
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…ird Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2026, and host a corporate…
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced multiple encore presentations sup…
View source ↗ - Newsseekingalpha.com·72d ago·Positive
…oes Not Require The Fastest Approval Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qual…
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·103d ago·Negative
Taysha Gene Therapies Q2 Earnings Call Highlights Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.
View source ↗ - Newsglobenewswire.com·103d ago·Neutral
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027
View source ↗
Earnings
Thu, Mar 18(in 4 months)
Consensus estimate $-0.11 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.10 vs $-0.13beat
- Tue, Aug 11$-0.13 vs $-0.11miss
- Wed, May 6$-0.12 vs $-0.10miss
- Thu, Mar 19$-0.08 vs $-0.11beat
- Tue, Nov 4$-0.09 vs $-0.09beat
- Tue, Aug 12$-0.09 vs $-0.07miss
Estimates and results for TSHA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TSHA officers and directors.
- Bought
- $21.2m
- Sold
- $8.0m
8 trades
21 trades
- Nagendran Sukumarsold
- Nagendran Sukumarsold
- Alam Kamransold
- Nagendran Sukumarsold
- Nolan Sean P.sold
- Alam Kamransold
- Nagendran Sukumarsold
- Nolan Sean P.sold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TSHA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
